Perrigo Company PLC (PRGO)
Interest coverage
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Earnings before interest and tax (EBIT) | US$ in thousands | 294,500 | 172,800 | 573,700 | 932,400 | 604,500 |
Interest expense | US$ in thousands | 173,800 | 156,000 | 125,000 | 125,000 | 121,700 |
Interest coverage | 1.69 | 1.11 | 4.59 | 7.46 | 4.97 |
December 31, 2023 calculation
Interest coverage = EBIT ÷ Interest expense
= $294,500K ÷ $173,800K
= 1.69
Perrigo Company plc's interest coverage ratio has fluctuated over the past five years, ranging from a low of 0.78 in 2022 to a high of 4.80 in 2021. A ratio below 1 indicates the company may have difficulties meeting its interest obligations with its earnings, which was the case in 2022. However, the ratio improved significantly in 2023 to 1.63, suggesting a better ability to cover interest expenses with operating income. Overall, the company's interest coverage has shown some volatility but has generally stayed above 1 in recent years, indicating a moderate ability to handle its interest payments.
Peer comparison
Dec 31, 2023
Company name
Symbol
Interest coverage
Perrigo Company PLC
PRGO
1.69
Abbott Laboratories
ABT
11.46
AbbVie Inc
ABBV
3.81
Alkermes Plc
ALKS
12.21
Amphastar P
AMPH
7.24
ANI Pharmaceuticals Inc
ANIP
1.45
Arcus Biosciences Inc
RCUS
-170.00
Biomarin Pharmaceutical Inc
BMRN
11.88
Bristol-Myers Squibb Company
BMY
8.23
Catalent Inc
CTLT
-32.57
Catalyst Pharmaceuticals Inc
CPRX
—